Steve Pakola leaves Thrombogenics for Amakem
This article was originally published in Scrip
Dr Steve Pakola has taken the role of CMO at Amakem, having previously served as CMO of Thrombogenics, where he played a pivotal role in the development of the company's lead product, ocriplasmin, which is under review in Europe as a treatment for symptomatic vitreomacular adhesion and has been filed for priority review in the US. Dr Pakola has been replaced at Thrombogenics by Dr Aniz Girach, who joined the company a year and a half ago as global head of clinical ophthalmology and was previously vice-president of international clinical development of ophthalmology at Alcon.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.